Paradigm Peptides: The Adjudicated Case Record
Updated August 21, 2026
Paradigm Peptides produced the one criminal case in the research-peptide market to reach final judgment. The storefront went offline in March 2024; guilty pleas from owner Matthew Kawa and employee Jennifer Stechkober followed on December 10, 2025; sentences were imposed July 30, 2026 at the South Bend federal courthouse — 70 months for Kawa, 16 for Stechkober.
Chronology
| Date | Event |
|---|---|
| March 2024 | The Paradigm Peptides storefront goes offline |
| After March 2024 | The domain paradigmpeptides.is surfaces under a near-identical name; its own pages state no affiliation with the defunct company |
| December 10, 2025 | Guilty pleas entered by Matthew Kawa, 48 (owner), and by Jennifer Stechkober, 32 — Kawa's sister, described in the record as the firm's principal employee |
| July 30, 2026 | Sentences imposed, N.D. Indiana (South Bend federal court) — Kawa: 70 months' imprisonment, one year of supervised release, $5 million forfeiture; Stechkober: 16 months |
The charges, as the record states them
Kawa's plea covered two offenses, worded here as the record words them: "introducing unapproved drugs into interstate commerce with intent to defraud and mislead," and illegal importation of merchandise. Stechkober entered her own guilty plea. This index reports the offenses in the record's terms and characterizes them no further; each legal statement on this page rests on the court record as reported by CBS News and by federal prosecutors in Indiana's northern district.
Products at issue
The products in the case included peptides, hCG, and SARMs. One finding stands out for anyone who relies on supplier labeling: per the record, goods sold under SARM labeling contained testosterone — a substance in Schedule III. That is a direct mismatch between label and contents, on top of the unapproved sale itself — the failure mode that third-party identity testing exists to detect, and the reason this index's evaluation standard asks whether a vendor's certificate of analysis establishes identity by mass spectrometry, not by a purity percentage alone.
Lookalike domain
The original Paradigm Peptides storefront has been offline since March 2024. The later-registered paradigmpeptides.is carries its own statement of non-affiliation with the defunct operation. This index records that statement without evaluating the site behind it; the general pattern — defunct vendor brands attracting new registrants — recurs elsewhere in the vendor record, and a buyer encountering any domain trading on a closed vendor's name has no documented basis for assuming continuity with the original business.
Position in the enforcement record
Within the 2024–2026 enforcement sequence, Paradigm Peptides occupies a tier of its own. Warning letters, such as the December 2024 and March 2026 batches, are agency findings awaiting response. The June 2025 Amino Asylum raid halted a vendor's operations, but that record contains no documented court outcome. Paradigm Peptides is the case that ran to completion — pleas entered, sentences imposed, forfeiture ordered — which makes its findings, including the label-contents mismatch, court-established facts, not allegations. The case sits in context on the enforcement timeline and in the Paradigm Peptides entry of the vendor index.
A note on misattribution
The Kawa and Stechkober pleas are frequently blended into coverage of other vendor shutdowns, particularly Amino Asylum's. They belong to Paradigm Peptides alone. During this index's own compilation, two separate machine-generated search summaries attributed the same names to both companies — the reason this record cites only the named primary reporting below.
Sources
- CBS News — report on the Paradigm Peptides sentencing (verified against the primary report)
- Office of the United States Attorney, Northern District of Indiana — public sentencing announcement of July 30, 2026
Further reading
- Paradigm Peptides' 2020 FDA–FTC warning letter — the earlier of the two FDA letters the U.S. Attorney's sentencing statement mentions.
- Artemis Labs — Paradigm Peptides alternatives (vendor-published account)
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.